PapersFlow Research Brief
HIV Research and Treatment
Research Guide
What is HIV Research and Treatment?
HIV Research and Treatment encompasses studies on immune activation, vaccine development, viral reservoirs, antiretroviral therapy, immune responses to HIV infection, neurocognitive disorders associated with HIV, antibodies targeting HIV, and therapeutic interventions.
This field includes 137,479 works focused on HIV/AIDS aspects such as antiretroviral therapy and viral dynamics. Palella et al. (1998) reported declining morbidity and mortality among patients with advanced HIV infection due to intensive antiretroviral therapies. Cohen et al. (2011) demonstrated that early antiretroviral therapy reduced HIV-1 sexual transmission rates and clinical events in the HPTN 052 trial.
Topic Hierarchy
Research Sub-Topics
HIV Latency and Viral Reservoirs
Researchers study the establishment, maintenance, and reactivation of latent HIV reservoirs in resting CD4+ T cells and other sanctuaries. Single-cell analyses and epigenetic profiling identify barriers to eradication despite antiretroviral therapy.
Broadly Neutralizing Antibodies Against HIV
This field focuses on isolation, maturation, and engineering of bNAbs targeting conserved epitopes on HIV Env glycoprotein. Clinical trials evaluate passive infusion and vaccine-induced bNAb responses for prevention and therapy.
Immune Activation in Chronic HIV Infection
Studies investigate persistent inflammation, microbial translocation, and T cell exhaustion driving non-AIDS comorbidities like cardiovascular disease. Interventions target innate immune sensors and checkpoint inhibitors to restore homeostasis.
HIV Vaccine Development Strategies
Researchers design immunogens to elicit bNAbs, cytotoxic T lymphocytes, and durable mucosal immunity using prime-boost regimens and mRNA platforms. Correlate analyses from trials like RV144 and HVTN 702 guide next-generation approaches.
Neurocognitive Disorders in HIV
This sub-topic examines HIV-associated neurocognitive disorders (HAND) from mechanisms of viral neuroinvasion to biomarkers and therapeutic interventions. Longitudinal cohorts assess impacts of aging, ART, and comorbidities on brain function.
Why It Matters
Antiretroviral therapy has transformed HIV into a manageable condition, as shown by Palella et al. (1998) who observed declines in morbidity and mortality from intensive therapies among advanced HIV patients. Connor et al. (1994) found that zidovudine given antepartum, intrapartum, and to newborns reduced maternal-infant HIV transmission by approximately two-thirds in untreated pregnant women. Recent grants, including amfAR's five new HIV cure-focused projects and NIH's $8.4 million to OHSU scientists, support cure strategies at ART initiation, addressing reservoirs and enabling ART-free control.
Reading Guide
Where to Start
"Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection" by Palella et al. (1998) because it provides foundational evidence on antiretroviral therapy's impact on clinical outcomes, accessible for understanding treatment evolution.
Key Papers Explained
Palella et al. (1998) established declines in morbidity from intensive antiretroviral therapies, building on Connor et al. (1994)'s demonstration of zidovudine reducing maternal-infant transmission by two-thirds. Ho et al. (1995) and Perelson et al. (1996) quantified rapid virion and infected cell turnover, informing dynamics modeled in Neumann et al. works, while Cohen et al. (2011) extended this to prevention via early therapy in HPTN 052.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints explore combination immunotherapy for ART-free control, including "Correlates of HIV-1 control after combination immunotherapy" and "CD8 + T cell stemness precedes post-intervention control of HIV viraemia," alongside amfAR and NIH grants for cure strategies at ART initiation.
Papers at a Glance
In the News
amfAR Awards New HIV Cure-Focused Research Grants ...
amfAR has awarded new Target Grants to support innovative research projects aimed at curing HIV, funding five grants in a single round for the very first time. This brings total funding for new gra...
NIH awards OHSU scientists, collaborators $8.4 million to ...
The team has been awarded $8.4 million from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Sacha will work with collaborators at OHSU as well as Wei...
Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
The purpose of this Notice of Funding Opportunity (NOFO) is to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart ...
Correlates of HIV-1 control after combination immunotherapy
The identification of therapeutic strategies to induce sustained antiretroviral therapy (ART)-free control of HIV infection is a major priority 1 . Combination immunotherapy including HIV vaccinati...
Long-Term HIV Control: Could this Combination Therapy Be the Key?
**Funding:**The UCSF amfAR Combination Trial was funded by amfAR: The Foundation for AIDS Research (109301-59-RGRL). The prospective ATI study was funded by the Bill & Melinda Gates Foundation (INV...
Code & Tools
> **> Advanced analytics platform for HIV/AIDS medical data, featuring machine learning predictions, transmission analysis, treatment efficacy eval...
Optima HIV is a software tool that assists national decision-makers and program managers in achieving maximum impact for every dollar invested in t...
Examples of systems that have already been implemented in Starsim include sexually transmitted infections (HIV, HPV, and syphilis, including co-tra...
`ushr` is an open-source R package that models the decline of HIV during ART using a popular mathematical framework. The package can be applied to ...
An HIV case reporting IG for the DISI architecture. ## Publication This ImplementationGuide is published in the following locations: * Continuous...
Recent Preprints
Pharmacological advances in HIV treatment: from ART to long ...
Human immunodeficiency virus (HIV) remains a global public health challenge, affecting millions worldwide despite significant advancements in antiretroviral therapy (ART). While ART has transformed...
Correlates of HIV-1 control after combination immunotherapy
The identification of therapeutic strategies to induce sustained antiretroviral therapy (ART)-free control of HIV infection is a major priority 1 . Combination immunotherapy including HIV vaccinati...
Long-Term HIV Control: Could this Combination Therapy ...
### Topics * AIDS and HIV * Infectious Disease ## Recommended Reading Two researchers look at a screen showing microscopic images relevant to research on long COVID. * Research * Jan. 21, 2026 ...
CD8 + T cell stemness precedes post-intervention control of HIV viraemia
Interventions to induce lasting human immunodeficiency virus (HIV) remission are needed to obviate the requirement for lifelong antiretroviral therapy. Durable post-intervention control (PIC) of vi...
AIDS Research and Treatment
_AIDS Research and Treatment_ is an open access journal publishing original research articles, review articles, and clinical studies focused on all aspects of HIV and AIDS, from the molecular basis...
Latest Developments
Recent developments in HIV research and treatment as of February 2026 include the initiation of a promising Phase 1 clinical trial for an HIV vaccine (IAVI G004) using a novel immunogen sequence to induce broadly neutralizing antibodies, with the first doses administered in December 2025 (IAVI). Additionally, a new HIV drug, lenacapavir, received FDA approval in June 2025 for HIV prevention, which could significantly reduce infection rates (UofuHealth). Other advancements include updated WHO guidelines on HIV management released in January 2026 and ongoing research into long-acting injectable PrEP options such as twice-yearly lenacapavir (WHO; SF AIDS Foundation).
Sources
Frequently Asked Questions
What caused declining morbidity and mortality in advanced HIV patients?
Intensive antiretroviral therapies led to declines in morbidity and mortality due to AIDS. Palella et al. (1998) documented this trend among patients with advanced Human Immunodeficiency Virus Infection.
How does early antiretroviral therapy prevent HIV-1 transmission?
Early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events. Cohen et al. (2011) showed personal and public health benefits in the HPTN 052 trial.
What is the revised classification system for HIV infection?
The 1993 revised system emphasizes the clinical importance of CD4+ T-lymphocyte count in categorizing HIV-related conditions. Castro et al. (1993) introduced this for surveillance among adolescents and adults, replacing the 1986 system.
How effective was zidovudine in reducing maternal-infant HIV transmission?
Zidovudine regimen given antepartum, intrapartum to mothers, and for six weeks to newborns reduced transmission risk by approximately two-thirds. Connor et al. (1994) reported this in pregnant women with mildly symptomatic HIV and no prior treatment.
What is the turnover rate of plasma virions and CD4 lymphocytes in HIV-1 infection?
Rapid turnover occurs in plasma virions and CD4 lymphocytes during HIV-1 infection. Ho et al. (1995) measured this dynamic in infected individuals.
What role does microbial translocation play in HIV?
Microbial translocation causes systemic immune activation in chronic HIV infection. Brenchley et al. (2006) identified this as a key mechanism.
Open Research Questions
- ? What therapeutic strategies induce sustained ART-free HIV control through combination immunotherapy including vaccination and broadly neutralizing antibodies?
- ? How does CD8+ T cell stemness contribute to post-intervention control of HIV viraemia after bNAb administration?
- ? What are the correlates of HIV-1 control following latency reversal and immune stimulation?
- ? Can cure strategies administered at ART initiation target viral reservoirs effectively?
- ? What pharmacological advances enable long-acting formulations beyond standard ART?
Recent Trends
Preprints from the last six months emphasize combination immunotherapy for ART-free HIV control, as in "Correlates of HIV-1 control after combination immunotherapy" and "CD8 + T cell stemness precedes post-intervention control of HIV viraemia." amfAR awarded five new HIV cure grants, and NIH provided $8.4 million to OHSU for related work, focusing on strategies at ART initiation amid ongoing pharmacological advances to long-acting therapies.
Research HIV Research and Treatment with AI
PapersFlow provides specialized AI tools for Immunology and Microbiology researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HIV Research and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Immunology and Microbiology researchers